Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

HCC-AI study group

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study'. Together they form a unique fingerprint.

Medicine & Life Sciences